MolDX publishes Medicare LCD for esophageal cancer testing; effective May 14, 2023

Lucid Diagnostics Inc.

Foundational LCD L39256 provides criteria for future coverage of molecular tests like EsoGuard.
LCD incorporates stakeholder feedback from 2022 draft, aligning with ACG guidelines and non-endoscopic testing.
Lucid plans to submit EsoGuard for Technical Assessment later this year after clinical utility data completion.
Company also highlights recent in-network agreement with MultiPlan to expand commercial payer coverage.
Lucid is a majority-owned subsidiary of PAVmed Inc. (PAVM).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.